AstraZeneca Pharma India CFO Bhavana Agrawal resigns, moves to regional role

Cfo ResignedManagement Changes View source PDF

ASTRAZEN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

-2.3%1-day move

₹8068.00

prior close

—

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

————-2.3-0.7+0.5+0.1——————

Up moveDown movePending

AI summary

Ms. Bhavana Agrawal, Executive Director and CFO of AstraZeneca Pharma India, has resigned as CFO effective close of business on August 31, 2026. Reason given is her appointment to a regional role within the AstraZeneca Group. No replacement CFO has been announced yet. She holds NIL shares in the company.

Likely market impact

CFO transition tied to internal group rotation, not a red flag. Watch for naming of replacement and continuity in financial reporting.